2026-06-07T16:09:39Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1289712025-12-16T00:47:32Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc García Rubia, Alfonso author Lasala, Fátima author Ginex, Tiziana author Morales Tenorio, Marcos author Olal, Catherine author Heung, Michelle author Oquist Phillips, Mayra Paola author Galindo, Inmaculada author Cuesta Geijo, Miguel Aprimengel author Casasnovas, Jose María author Campillo, Nuria Eugenia author Canales Mayordomo, María Ángeles author Alonso, Covadonga author Martínez, Ana author Muñoz Fontela, César author Delgado, Rafael author Gil, Carmen author 2023-04-27 Ebola virus (EBOV) is a single-strand RNA virus belonging to the Filoviridae family, which has been associated to most Ebola virus disease outbreaks to date, including the West African and the North Kivu epidemics between 2013 and 2022. This unprecedented health emergency prompted the search for effective medical countermeasures. Following up on the carbazole hit identified in our previous studies, we synthetized a new series of compounds, which demonstrated to prevent EBOV infection in cells by acting as virus entry inhibitors. The in vitro inhibitory activity was evaluated through the screening against surrogate models based on viral pseudotypes and further confirmed using replicative EBOV. Docking and molecular dynamics simulations joined to saturation transfer difference-nuclear magnetic reso-nance (STD-NMR) and mutagenesis experiments to elucidate the biological target of the most potent compounds. Finally, in vitro metabolic stability and in vivo pharmacokinetic studies were performed to confirm their therapeutic potential. Alfonso Garcia-Rubia, Fátima Lasala, Tiziana Ginex, Marcos Morales-Tenorio, Catherine Olal, Michelle Heung, Paola Oquist, Inmaculada Galindo, Miguel Ángel Cuesta-Geijo, José M. Casasnovas, Nuria E. Campillo, Ángeles Canales, Covadonga Alonso, Ana Martínez, César Muñoz-Fontela, Rafael Delgado, and Carmen Gil Journal of Medicinal Chemistry 2023 66 (8), 5465-5483 10.1021/acs.jmedchem.2c01785 https://hdl.handle.net/20.500.14352/128971 https://doi.org/10.1021/acs.jmedchem.2c01785 https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01785 N′-Phenylacetohydrazide derivatives as potent Ebola virus entry inhibitors with an improved pharmacokinetic profile